TY - JOUR
T1 - Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801)
T2 - complete republication
AU - Takahashi, Nobumasa
AU - Sawabata, Noriyoshi
AU - Kawamura, Masafumi
AU - Ohtsuka, Takashi
AU - Horio, Hirotoshi
AU - Sakaguchi, Hirozou
AU - Nakayama, Mitsuo
AU - Yoshiya, Katsuo
AU - Chida, Masayuki
AU - Hoshi, Eishin
N1 - Publisher Copyright:
© 2016, The Japanese Association for Thoracic Surgery.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background: Local therapy for stage I non-small cell lung cancer (NSCLC) is divided into surgical and radiation treatment, and given to patients unable to tolerate a lobectomy. A prospective phase II study of cases that received stereotactic body radio therapy (SBRT) (JCOG0403) revealed an overall 3-year survival rate (3-YSR) of 76.0 %, 3-year relapse free survival rate (3-YRFS) of 69.0 %, and rate of morbidity of grade 3 or greater of 9 %. However, few prospective multicenter studies have reported regarding surgery for high-risk stage I NSCLC patients. Methods: We investigated this issue in the setting of a prospective multicenter observational study. Thirty-two high-risk NSCLC patients (30 males, 2 females; median age 74 years, 61–85 years) were analyzed. Results: Two (6.3 %) showed morbidity of grade 3 or greater, though there were no postoperative deaths. The margin local control rate was 97.0 % (surgical margin recurrence, 1) and local recurrence control rate was 75.0 % (ipsilateral thorax recurrence, 8), while the 3-YSR and 3-YRFS was 79.0 and 75.9 %, respectively. Conclusion: A sublobar pulmonary resection for patients unable to tolerate a lobectomy with stage I NSCLC was shown to be safe and provided results comparable with those of SBRT.
AB - Background: Local therapy for stage I non-small cell lung cancer (NSCLC) is divided into surgical and radiation treatment, and given to patients unable to tolerate a lobectomy. A prospective phase II study of cases that received stereotactic body radio therapy (SBRT) (JCOG0403) revealed an overall 3-year survival rate (3-YSR) of 76.0 %, 3-year relapse free survival rate (3-YRFS) of 69.0 %, and rate of morbidity of grade 3 or greater of 9 %. However, few prospective multicenter studies have reported regarding surgery for high-risk stage I NSCLC patients. Methods: We investigated this issue in the setting of a prospective multicenter observational study. Thirty-two high-risk NSCLC patients (30 males, 2 females; median age 74 years, 61–85 years) were analyzed. Results: Two (6.3 %) showed morbidity of grade 3 or greater, though there were no postoperative deaths. The margin local control rate was 97.0 % (surgical margin recurrence, 1) and local recurrence control rate was 75.0 % (ipsilateral thorax recurrence, 8), while the 3-YSR and 3-YRFS was 79.0 and 75.9 %, respectively. Conclusion: A sublobar pulmonary resection for patients unable to tolerate a lobectomy with stage I NSCLC was shown to be safe and provided results comparable with those of SBRT.
KW - Conservative limited pulmonary resection
KW - Non-small cell lung cancer
KW - Prospective study
KW - Stage I
UR - http://www.scopus.com/inward/record.url?scp=84970983757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84970983757&partnerID=8YFLogxK
U2 - 10.1007/s11748-016-0662-z
DO - 10.1007/s11748-016-0662-z
M3 - Article
C2 - 27234224
AN - SCOPUS:84970983757
SN - 1863-6705
VL - 64
SP - 470
EP - 475
JO - General thoracic and cardiovascular surgery
JF - General thoracic and cardiovascular surgery
IS - 8
ER -
